Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Skye Bioscience, Inc. (Nasdaq: SKYE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Skye is a Nevada corporation and clinical-stage biotechnology company focused on metabolic health, and its filings offer structured insight into its financial condition, clinical programs, and material corporate events.
Investors researching SKYE can use this page to review current and historical reports such as Form 8-K, where Skye has furnished press releases on topics including topline CBeyond™ Phase 2a data for nimacimab, financial results for specific reporting periods, and other corporate updates. These 8-K filings link clinical milestones—such as Phase 2a obesity trial readouts, extension study enrollment, and Phase 1b results in metabolic-associated steatotic liver disease—to the company’s formal disclosure record.
Through Stock Titan, Skye’s filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, allowing users to quickly understand the context of complex clinical and financial information. This includes highlighting how Skye describes nimacimab’s development status, safety and efficacy data reported in furnished press releases, and the company’s stated plans for future clinical studies.
In addition to event-driven Form 8-Ks, users can locate Skye’s annual and quarterly reports, once available, to examine consolidated financial statements, research and development expenditures, and risk factor discussions related to its obesity and metabolic health programs. The filings page also provides a path to monitor any future ownership and insider transaction disclosures, such as Form 4 filings, when they are reported. Together, these documents form a detailed regulatory history that supports deeper analysis of SKYE as a clinical-stage biotech issuer.
Skye Bioscience reported that its Chief Financial Officer, Kaitlyn Arsenault, received a grant of stock options on February 6, 2026. The award covers 125,000 options to buy common stock at an exercise price of $0.82 per share. The options vest in equal monthly installments over a four-year period beginning January 19, 2026, aligning her long-term compensation with the company’s share performance.
Skye Bioscience Chief Scientific Officer granted 150,000 stock options. Christopher Twitty received a stock option for 150,000 shares of common stock at an exercise price of $0.82 per share on February 6, 2026. All 150,000 options are held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026, meaning portions become exercisable each month over that timeframe rather than all at once.
Skye Bioscience director Deborah H. Charych received stock options for 35,000 shares of common stock. The options have an exercise price of $0.82 per share and were granted on February 6, 2026. They vest in equal monthly installments over a one-year period beginning January 19, 2026, and expire on February 6, 2036.
Skye Bioscience director Annalisa Jenkins received a grant of stock options covering 35,000 shares of common stock on February 6, 2026. The options have an exercise price of $0.82 per share and expire on February 6, 2036.
According to the filing, the option vests in equal monthly installments over a one-year period beginning January 19, 2026. After this grant, Jenkins beneficially owns 35,000 stock options, held directly.
Skye Bioscience Chief Development Officer granted 125,000 options to buy common stock at an exercise price of $0.82 per share. The award was made on February 6, 2026 and expires on February 6, 2036.
The stock option vests in equal monthly installments over four years beginning January 19, 2026, meaning the officer earns the right to exercise more of the grant every month during that period, as long as service conditions are met.
Skye Bioscience Chief Medical Officer granted stock options. On February 6, 2026, Chief Medical Officer Puneet S. Arora received a stock option to buy 125,000 shares of Skye Bioscience common stock at an exercise price of $0.82 per share. The option vests in equal monthly installments over four years beginning January 19, 2026, and is held directly by the reporting person.
Skye Bioscience Chief Executive Officer and director Punit Dhillon reported a grant of stock options. On February 6, 2026, he was awarded an option to buy 280,000 shares of common stock at an exercise price of $0.82 per share, held directly.
The option vests in equal monthly installments over a four-year period beginning January 19, 2026 and expires on February 6, 2036. Following this grant, Dhillon beneficially owns 280,000 derivative securities in the form of this stock option.
Skye Bioscience reported interim results from the combination cohort of its Phase 2a extension study of nimacimab for obesity. Nineteen participants who completed 26 weeks entered a further 26-week blinded extension, remaining on either nimacimab plus semaglutide or placebo plus semaglutide.
In the nimacimab plus semaglutide arm, mean weight loss was 14.4% at 26 weeks; seven completers lost an additional 7.9% over the extension, for 22.3% mean loss at 52 weeks. In the placebo plus semaglutide arm, mean weight loss was 13.9% at 26 weeks; seven completers lost an additional 5.8%, for 19.7% mean loss at 52 weeks. The combination remained safe and well tolerated, with no serious adverse events or adverse events of special interest reported.
The company expects full topline Phase 2a extension data, including nimacimab monotherapy and a 13-week off-therapy follow-up, in Q3 2026. It currently expects its capital to fund operations and key clinical milestones into the fourth quarter of 2026, excluding anticipated clinical and manufacturing costs for a proposed higher-dose Phase 2b trial.
Skye Bioscience furnished an update on its business and reported financial results for the period ended September 30, 2025 via a press release attached to a Form 8-K.
The company submitted the press release as Exhibit 99.1 under Item 2.02. Consistent with General Instruction B.2, this information is furnished and not deemed filed under the Exchange Act.
Skye Bioscience (SKYE) filed its Q3 2025 10‑Q, reporting wider losses as it advances obesity drug development. The company posted a net loss of $12,754,660 for the quarter. Operating expenses rose to $13,264,534, driven by research and development of $9,357,444 and general and administrative costs of $3,907,090.
Liquidity remained solid for near‑term plans: cash and cash equivalents were $18,441,079 and short‑term investments were $16,871,229, totaling $35,312,308 as of September 30, 2025. Total stockholders’ equity was $32,836,185. As of November 7, 2025, 32,057,461 shares were outstanding.
In its CBeyond Phase 2a study, nimacimab monotherapy did not meet the primary endpoint for weight loss versus placebo. However, the combination of nimacimab 200 mg with semaglutide showed greater weight loss than semaglutide alone at 26 weeks and maintained a favorable safety profile. The 26‑week extension enrolled 43 patients, with data expected in Q1 2026.